Karyopharm Therapeutics (KPTI) EPS (Basic) (2012 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly EPS (Basic) came in at -$2.32 in Q2 2026, up 46.41% on a YoY basis from -$1.58 in Q2 2025, and up 58.48% quarter-over-quarter from -$5.58 in Q4 2025.
Powered by 
Analysis
Karyopharm Therapeutics (KPTI) EPS (Basic) (2012 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has reported EPS (Basic) for 15 consecutive years, with -$2.32 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EPS (Basic) rose 46.41% year-over-year to -$2.32; the trailing twelve-month figure through Jun 2026 stood at -$6.86 (up 52.2% YoY), and the FY2025 full-year result was -$14.16, down 50.38% from the prior year.
- EPS (Basic) grew to -$2.32 in Q2 2026 per KPTI's latest filing, from -$5.58 in the prior quarter.
- Across five years, EPS (Basic) topped out at $2.95 in Q2 2024 and bottomed at -$9.24 in Q2 2022.
- Historically, EPS (Basic) has averaged -$4.62 across 5 years, with a median of -$4.51 in 2023.
- The sharpest annual moves came in 2024 and 2025: EPS (Basic) jumped 168.81% in 2024, then slumped 246.56% in 2025.
- Over 5 years, EPS (Basic) stood at -$7.22 in 2022, then grew by 23.5% to -$5.53 in 2023, then soared by 31.27% to -$3.8 in 2024, then plunged by 46.86% to -$5.58 in 2025, then surged by 58.48% to -$2.32 in 2026.
- According to Business Quant data, EPS (Basic) over the past three periods registered -$2.32, -$5.58, and -$3.82 for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 2.30 |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 2.04 |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | -0.54 |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 1.68 |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | -0.04 |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 0.33 |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | -3.06 |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 2.92 |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | 7.82 |
| 10 | Karyopharm Therapeutics | 51.80 Mn | -13.31 Mn | 32.35 Mn | -2.32 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.32 |
| Dec 31, 2025 | -5.58 |
| Sep 30, 2025 | -3.82 |
| Jun 30, 2025 | -4.32 |
| Mar 31, 2025 | -2.77 |
| Dec 31, 2024 | -3.80 |
| Sep 30, 2024 | -3.85 |
| Jun 30, 2024 | 2.95 |
| Mar 31, 2024 | -4.85 |
| Dec 31, 2023 | -5.53 |
| Sep 30, 2023 | -4.52 |
| Jun 30, 2023 | -4.29 |
| Mar 31, 2023 | -4.51 |
| Dec 31, 2022 | -7.22 |
| Sep 30, 2022 | -6.79 |
| Jun 30, 2022 | -9.24 |
| Mar 31, 2022 | -8.01 |
| Dec 31, 2021 | 7.71 |
| Sep 30, 2021 | -10.30 |
| Jun 30, 2021 | -10.69 |